Logo Image
Opinion|Videos|December 17, 2024

Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH

Key Takeaways

  • Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
  • Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
SHOW MORE

Steven Nathan, MD, discusses how the study on inhaled treprostinil for CTD-PAH demonstrates its comparable efficacy to intravenous and subcutaneous forms, with a better safety profile, which could lead to improved patient adherence and management of CTD-PAH.

Episodes in this series
  1. Briefly describe the abstract “Inhaled Treprostinil for the Treatment of Connective Tissue-Associated Pulmonary Arterial Hypertension.”
    1. What was the objective of this study?
    2. How was this study designed/what methodology was used?
    3. What results were presented?
  2. What are your key takeaways from this study, and what are the clinical implications in utilizing inhaled treprostinil compared with intravenous or subcutaneous treprostinil for connective tissue disease-associated PAH?